PHIO News and Press, Phio Pharmaceuticals Corp. From 01/25/23

Phio Pharma ( NASDAQ: PHIO ) said it had approved a reverse stock split of its shares at a ratio of 1-for-12, which will be effective at 12:01 a.m. Eastern Time on Jan 26. ( PHIO ) is trading ~10% lower premarket. The reverse stock split is being done to increase ...

Phio Showcases Innovations in Dermatology Cancers at 2023 Dermatology Summit in San Francisco PR Newswire MARLBOROUGH, Mass. , Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals (Nasdaq: PHIO), a clinical stage biotechnology company whose proprietary INTASYL ...

Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors PR Newswire MARLBOROUGH, Mass. , Jan. 6, 2023 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO) to...

Phio Pharmaceuticals press release ( NASDAQ: PHIO ): Q3 GAAP EPS of -$0.26. At September 30, 2022, the Company had cash of $14.5 million as compared with $24.1 million at December 31, 2021. For further details see: Phio Pharmaceuticals GAAP EPS of -$0.26

Phio Announces New Appointments to Leadership Team, Reports on Third Quarter 2022 Financial Results and Provides Business Update PR Newswire New executive team leading development of Phio's RNAi compounds and proprietary INTASYL™ platform Continuing enro...

Phio Pharmaceuticals Announces Study Results at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10th and 11th PR Newswire Phio's INTASYL™ compounds demonstrated activity against multiple protein targets including PD-1, BRD4,...

Phio Pharmaceuticals Announces Upcoming Presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) PR Newswire MARLBOROUGH, Mass. , Oct. 6, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage bi...

Clinical stage biotechnology company Phio Pharmaceuticals ( NASDAQ: PHIO ) appointed Robert Bitterman interim executive chairman. Bitterman has served as a director since 2012. Also, Robert Ferrara, chairman of the audit committee, is appointed lead...

Phio Pharmaceuticals Announces Appointment of Robert Bitterman as Executive Chairman PR Newswire MARLBOROUGH, Mass. , Sept. 29, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing the next ge...

Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz Munich at the 9th Immunotherapy of Cancer Conference PR Newswire MARLBOROUGH, Mass. , Sept. 22, 2022 /PRN...